Mandate

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 415.9 million

Vinge has advised Hansa Biopharma in connection with a directed share issue through which the company raises proceeds of SEK 415.9 million before transaction costs.

Hansa Biopharma is a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.

Vinge’s team consisted of Dain Hård Nevonen, Amanda Knutsson, Anders Sundin Lundberg and Petter Hellgren.

Related

Vinge advises Spetses Investments and Bacara Holdings on the public offer for IRRAS

A bid consortium, acting through IR Holding Bidco Inc, has announced and completed a public offer to the shareholders of IRRAS AB (publ). The consortium included, among others, IRRAS’ two largest shareholders, Spetses Investments Ltd and Bacara Holdings Limited, both advised by Vinge.
October 03, 2023

Vinge advises SAGA Diagnostics AB on convertible note issue

SAGA Diagnostics AB, a cancer diagnostics and disease monitoring company, has carried out a convertible note issue of approximately SEK 144 million. Vinge advised SAGA Diagnostics in connection with the transaction.
September 28, 2023

Vinge advises Repligen Corporation in connection with the acquisition of Metenova

Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).
September 27, 2023